Corvionis

Corvionis

Cross-system execution partner for early clinical development in advanced therapies

We support biotechnology and advanced therapy companies in advancing integrated development programs across global regulatory and clinical systems, from strategic design and IND support to early clinical development and market access. Our focus is to reduce structural failure risks in early clinical development.
Contact us

Our core positioning

Corvionis is a Germany-based life science strategy and execution partner focused on advanced therapies, early clinical development, and high-complexity translational medicine programs.

Our core mission is to build executable development pathways across science, regulation, clinical development, and commercialization, while resolving the structural gaps that commonly arise between countries, systems, and stakeholders.

These gaps often occur between:

  • Scientific research and clinical development
  • Regulatory pathways and real-world execution
  • Different regulatory systems across Europe, the United States, China, and other regions
  • Hospitals, CROs, and industry collaboration networks
  • Investment decisions and development realities

We view these structural disconnects, rather than science itself, as one of the main reasons why promising life science programs fail to progress.

Our focus areas

Advanced therapies

Complex therapeutic modalities requiring integrated regulatory, clinical, and execution planning.

Cell & gene therapy

High-complexity programs where translational, manufacturing, clinical, and regulatory systems must be aligned early.

Regenerative medicine

Development programs requiring deep translational and early clinical execution capabilities.

Oncology & precision medicine

Programs where clinical feasibility, biomarker strategy, and development pathway design are critical.

Translational medicine

Bridging scientific research, clinical relevance, and development execution.

Early clinical development

IND, FIH, Phase I readiness, and early clinical value inflection points.

Global presence and strategic coverage

Region Strategic role
Germany Regulatory strategy, clinical development, and European collaboration base
Europe Strategic partnerships, industry networks, and market expansion
China Cross-border execution, industrial partnerships, and market access
United States Capital markets, business development, and international collaboration opportunities